Logiscreen

ClearPoint Neuro Inc

$12.89
Market Cap 382.37M
ROE -141.0%
Gross Margin 64.0%
Debt/Equity 3.4
Current Ratio 5.8
Revenue QoQ 42.9%
EPS QoQ 0.5%
F-Score 3

About

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide.

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Devices

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-14.61
vs median 33.61
P/B
22.55
vs median 2.16
ROE
-1.41
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics